Skip to main content
| News

Versameb raises 6 million Swiss francs

17.07.2020

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Using revenues obtained from a seed financing round totaling 6 million Swiss francs, Versameb is planning to bring its VERSagile platform to the clinical development stage by the end of 2021, as detailed in a press release. Versameb has developed VERSagile in order to program mRNA sequences for improved therapeutic efficacy. To this end, a molecular algorithm developed by the Basel-based company is used. The molecules developed in this fashion are designed to be used in the areas of dermatology and oncology, as well in the field of myology, the study of muscle diseases.

The potential of the Versameb approach was recognized very early on by the investment and innovation promotion agency Basel Area Business & Innovation, which supported the company in 2017/18 by way of BaseLaunch, the organization’s biotech accelerator and incubator. Versameb has now set its sights on driving forward the development of the company. To this end, it has strengthened its management team with the addition of Klaas P. Zuideveld, who has been appointed Chief Development Officer (CDO). He will bring a “rare combination” of scientific excellence and management experience to the role, according to Friedrich Metzger, Co-Founder and CEO of Versameb, who was quoted in the press release.

With Versameb having already achieved important milestones with the VERSagile platform, Dr. Reinhard Ambros, Chairman of the Board of Versameb and former Head of the Novartis Venture Fund, is delighted to see “that the company is attracting excellent talent to perform on our strategic and operational goals and that it is enjoying strong support from its investors”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ground-breaking oncology being developed in the Basel Area

The Basel Area – covering northwestern Switzerland – has seen tremendous growth in recent years, and has become a true...

Read More
Genedata expanding its user network
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Genedata expanding its user network

The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site...

Read More
Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
1 2 3 64

Do you have a question? We'd like to hear from you.